Brief: Regenxbio announces completion of enrollment in pivotal trials of subretinal surabgene lomparvovec for WET AMD
06/10/2025 12:13
Oct 6 (Reuters) - Regenxbio Inc RGNX.O: REGENXBIO ANNOUNCES COMPLETION OF ENROLLMENT IN PIVOTAL TRIALS OF SUBRETINAL SURABGENE LOMPARVOVEC FOR WET AMD REGENXBIO INC - TOPLINE PIVOTAL DATA EXPECTED IN Q4 2026 Source text: ID:nPn6mtDMZa Further company coverage: RGNX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on REGENXBIO
See all newsBrief: Regenxbio says Sarepta To Pay $39 Million To Regenxbio Within 10 Days Of Effective Date
Regenxbio climbs as new director buys nearly $1 million of stock
Brief: Regenxbio Strengthens Board Of Directors With Appointment Of Greg Ciongoli
U.S. STOCKS ON THE MOVE-Strategy, Ecovyst, Azenta
U.S. STOCKS ON THE MOVE-Azenta, Qiagen NV, Capricor Therapeutics